Ozmosi | Erlotinib Drug Profile

Product Description

Erlotinib is used to treat certain types of non-small cell lung cancer that has spread to nearby tissues or to other parts of the body in patients who have already been treated with at least one other chemotherapy medication and have not gotten better. Erlotinib is also used in combination with another medication (gemcitabine [Gemzar]) to treat pancreatic cancer that has spread to nearby tissues or to other parts of the body and cannot be treated with surgery. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a605008.html)

Mechanisms of Action: EGFR Inhibitor, TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Company: Hoffmann-La Roche
Company Location:
Company Founding Year: 1896
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Erlotinib

Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Saudi Arabia, South Korea, Spain, Switzerland, Taiwan, Thailand, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 16

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT04341181	ProTarget	P2	Recruiting	Oncology Solid Tumor Unspecified	2029-04-30	12%	2025-07-26	Primary Endpoints
NCT02925234	DRUP	P2	Recruiting	Lymphoma, B-Cell\|Vision, Low\|Multiple Myeloma\|Hodgkin Lymphoma\|Lymphoma, Non-Hodgkin\|Abnormalities, Multiple	2027-09-01	12%	2024-01-25	Primary Endpoints
NCT05442060	EGFR	P2	Recruiting	Non-Small-Cell Lung Cancer	2025-12-31	12%	2025-08-05	Primary Completion Date\|Primary Endpoints\|Treatments
2024-519070-39-00	UR1909	P2	Recruiting	Renal Cell Carcinoma	2025-09-05		2025-05-02	Treatments
NCT01927744	NCI-2014-01390	P2	Completed	Squamous Cell Carcinoma\|Head and Neck Cancer	2025-01-06	12%	2025-01-11	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2018-002190-21	ROME	P2	Completed	Breast Cancer\|Intestinal Cancer\|Non-Small-Cell Lung Cancer	2024-09-06		2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT03110484	NCT03110484	P2	Recruiting	Biliary Tract Cancer	2023-06-14		2022-06-16	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT02091141	My Pathway	P2	Completed	Bladder Cancer	2023-05-24	52%	2024-02-23	Primary Completion Date\|Primary Endpoints
NCT03498521	CUPISCO	P2	Completed	Oncology Unspecified	2023-02-14	12%	2025-11-20	Patient Enrollment\|Primary Endpoints\|Treatments
NCT01013649	NCI-2011-01987	P3	Completed	Pancreatic Ductal Carcinoma\|Papillary Carcinoma\|Pancreatic Cancer\|Mucinous Adenocarcinoma\|Papillary Adenocarcinoma	2023-12-10		2025-10-09	Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT03137771	NRG-LU002	P2	Active, not recruiting	Non-Small-Cell Lung Cancer	2023-12-20		2025-03-12
jRCT2071200082	jRCT2071200082	P2	Active, not recruiting	Oncology Unspecified	2023-08-30
CTR20131154	CTR20131154	P3	Active, not recruiting	Non-Small-Cell Lung Cancer	None		2025-04-29	Treatments
2024-514269-20-00	I4T-MC-JVCY	P3	Active, not recruiting	Non-Small-Cell Lung Cancer	2024-12-16		2025-05-02	Treatments
CTR20130929	CTR20130929	P3	Active, not recruiting	Non-Small-Cell Lung Cancer	None		2025-04-29	Treatments
2024-514268-18-00	I4C-MC-JTBB	P2	Active, not recruiting	Non-Small-Cell Lung Cancer	2024-12-31	12%	2025-05-02	Treatments

Recent News Events

Date	Type	Title
10/09/2025	News Article	Computer-Aided Drug Design (CADD) Market Competitive Landscape Report – Towards Healthcare
09/04/2025	News Article	Sol-Gel Announces Health Canada Approval of EPSOLAY®
06/24/2025	News Article	Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
06/17/2025	News Article	Lung Cancer Research Foundation Announces Request for Proposals Focused on Curing EGFR Mutant Lung Cancers

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Erlotinib

Alternative Names: erlotinib, tarceva, osi-774, osi774, SGT210, SGT 210, SGT-210 Clinical Status: Inactive Latest Update: 2026-03-13 Latest Update Note: Clinical Trial Update